

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/34, 14/745, C12N 9/74, C07K 14/755	A1	(11) International Publication Number: WO 98/37086 (43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/NL98/00108 (22) International Filing Date: 23 February 1998 (23.02.98) (30) Priority Data: 97200533.4 24 February 1997 (24.02.97) EP (34) Countries for which the regional or international application was filed: NL et al. (71) Applicant (for all designated States except US): STICHTING SANQUIN BLOEDVOORZIENING [NL/NL]; Plesmanlaan 125, NL-1066 CX Amsterdam (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): HIEMSTRA, Harry [NL/NL]; Jan Mankesstraat 25hs, NL-1061 ST Amsterdam (NL). TER HART, Hendricus, Gerardus, Josephus [NL/NL]; Eemnesserweg 225, NL-1223 GG Hilversum (NL). PRINS-DE NIJS, Ingrid, Margaretha, Maria [NL/NL]; Stationstraat 33, NL-1749 EG Warmenhuizen (NL). HOEK, Pieter, Johannes [NL/NL]; Ben Lindeboomstraat 6, NL-2035 ST Haarlem (NL). OVER, Jan [NL/NL]; Chopinstraat 7, NL-3533 EJ Utrecht (NL). (74) Agent: SMULDERS, Th., A., H., J.; Verenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).	(81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD FOR REMOVING VIRUSES FROM PROTEIN SOLUTION BY NANOFILTRATION (57) Abstract Method for removing viruses, in particular small non-enveloped viruses, from a plasma derived product, such as Prothrombin Complex Concentrate. The method comprises prefiltration to remove contaminating high molecular weight proteins, followed by nanofiltration through a membrane with an average pore size of 15 nm. The method is capable of removing > 5.1 log Canine parvovirus and > 6.0 log Hepatitis A virus.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	Franco	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: METHOD FOR REMOVING VIRUSES FROM PROTEIN SOLUTION BY NANOFILTRATION

Field of the invention

This invention relates to methods to improve the viral safety of protein solutions, particularly blood products. More specifically, the invention relates to a method for removing
5 viruses, in particular small, non-enveloped viruses, from a plasma derived product, such as Prothrombin Complex Concentrate (PCC).

Background of the invention

10 Vitamin K-dependent plasma proteins, such as coagulation factors II, VII, IX and X and Proteins C and S, play an important role in the coagulation cascade. These factors isolated from plasma have been used since the early seventies to treat patients with a congenital deficiency of the afore-mentioned
15 proteins (e.g. Hemophilia B) and patients with an acquired deficiency (e.g. unbalanced coumarin therapy). The product which contains the therapeutic vitamin K dependent proteins is also known as Prothrombin Complex Concentrate (PCC).

Widely used methods to improve the viral safety of blood
20 products are chemical methods, such as the Solvent Detergent method, and heat treatment such as pasteurization or dry heat treatment. These methods are very effective for the removal or inactivation of enveloped viruses, such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and the Human Immunodeficiency
25 Virus (HIV). However, these methods are less effective for non-enveloped viruses.

It is conventional to treat PCC in-process with virucidal chemicals (e.g., 0.3% TNBP and 1.0% Tween 80) to inactivate
30 viruses. The viruses inactivated by such treatment are such enveloped viruses as Hepatitis B Virus, Hepatitis C Virus and Human Immunodeficiency Virus.

From the point of view from regulatory authorities there is a growing demand to prevent transmission by blood products

of non-enveloped viruses, such as Hepatitis A virus (HAV) and Human Parvovirus B19 (HPV). These viruses typically show chemical and heat resistance and have a small size of 25 and 20 nm respectively. The existing viral inactivation methods have been largely unsuccessful in the inactivation of the Hepatitis A Virus and especially Human Parvovirus B19.

Nanofiltration (15 nm) as a virus removing technique has been applied with success for highly purified proteins with a molecular weight smaller than 150 kD (WO 96/00237, Pharmacia). Attempts to use nanofiltration in order to remove Hepatitis A Virus and Parvovirus B19 from a solution, such as Prothrombin Complex Concentrate, however, remained without success.

Prothrombin Complex Concentrate is a product of rather low purity which contains many proteins (estimated at about 20 to 30) with a molecular weight up to about 20,000 kD. The therapeutic components in Prothrombin Complex Concentrate have a molecular weight of only approximately 70 kD. It has been discovered that the Prothrombin Complex Concentrate cannot pass a nanofilter with a pore size of 15 nm because of the presence therein of these contaminants which are high molecular weight proteins. Passage of the therapeutic proteins through the nanofilter is effectively blocked by clogging of the membrane by high molecular weight proteins. Only 35 nm filtration is feasible for Prothrombin Complex Concentrate, but this type of filtration does not remove Hepatitis A Virus and Human Parvovirus B19 (J. Römisch et al., Beitr. Infusions-ther. Transfusionsmed. Basel, Karger, 1996, vol. 33, 220-224).

An object of this invention is to provide a method which overcomes this problem.

An object of the subject invention is to provide a method for the removal or inactivation of small viruses, such as in particular non-enveloped viruses like HAV and parvoviruses, from a complex mixture, in particular plasma derived products, such as Prothrombin Complex Concentrate.

Another object of this invention is to provide an effective method for removing small viruses, in particular non-enveloped viruses, by nanofiltration from a blood serum or plasma derived mixture containing one or more members of the

group consisting of coagulation factors II, VII, IX and X and Proteins C and S, together with higher molecular weight proteins having a molecular weight of from about 200 kD, more particularly a molecular weight of from about 400 kD to about 20,000 kD.

Summary of the invention

The invention realizes the above objects by providing a method in which a complex mixture, in particular Prothrombin Complex Concentrate, is subjected to a pretreatment which improves the filtration properties of the protein solution. Typically, the pretreatment comprises a filtration, such as filtration over a 150 kD membrane in a tangential flow method at a transmembrane pressure of less than 0.5 bar. After the pretreatment, the PCC can be filtered through a 15 nm nanofilter.

Detailed description of the invention

More specifically, this invention relates to a method for removing viruses, in particular non-enveloped viruses, from a protein solution, comprising subjecting said mixture to a pretreatment which removes large proteins and subjecting the resulting product to nanofiltration which removes viruses. By applying the method of this invention to a protein solution which might be contaminated with (non-enveloped) viruses, it can be secured that the product obtained is substantially free of said viruses. So, the subject matter of this invention may be rephrased as a method for subjecting protein solutions to a treatment or processing which secures their substantial freedom of (non-enveloped) viruses.

The protein solution preferably is a blood derived protein solution, particularly a protein solution containing one or more proteins selected from the group consisting of coagulation factors II, VII, IX, X, Protein C, Protein S, albumin, antithrombin III, plasminogen, heparin cofactor II, Alpha-1-proteinase inhibitor, C1 inhibitor, transferrin, vitamin D-binding protein and immunoglobulin G. In a most

preferred embodiment of the invention, said protein solution is Prothrombin Complex Concentrate.

Generally, the large proteins which are to be removed by the pretreatment will have a molecular weight larger than about 150 kD, more particularly a molecular weight of from about 400 to about 20,000 kD. The large proteins are generally selected from the group consisting of fibrinogen, fibronectin, immunoglobulin M, coagulation factors VIII, XIII, von Willebrand factor and its multimeric forms, inter-alpha-(trypsin)-inhibitor, alpha-2-macroglobulin, C1q complement protein, C4 complement protein, apolipoprotein(a), apolipoprotein B-100 and ferritin.

In a particularly preferred embodiment of the invention, the pretreatment comprises membrane filtration over a membrane having a cut-off value of between about 100 to about 250 kD, preferably about 150 kD. It is preferred that the membrane filtration is carried out in a tangential flow filtration mode at a transmembrane pressure of less than 0.5 bar, and that during filtration a buffer is added to the retentate and the filtration process is stopped when the amount of filtrate is about 4 to 6 times the amount of starting material.

The nanofiltration will generally be carried out over a nanofilter having a cut-off value of between about 10 to about 30 nm, preferably about 15 nm, in a dead-end filtration mode. The resulting nanofiltrate (i.e. the filtrate obtained in the nanofiltration) is preferably directly concentrated by dia- or ultrafiltration, preferably in a hemodialysis cartridge.

The viruses to be removed, if present, generally are non-enveloped viruses, in particular non-enveloped viruses having a diameter of 20 nm or more, such as, in particular, Hepatitis A Virus, parvoviruses such as Human Parvovirus B19 and Canine Parvovirus, and Encephalomyocarditis Virus.

The method may include a virus inactivation, preferably before said pretreatment, by treating the protein solution with detergents such as ionic and/or non-ionic detergents in the presence of di- or trialkyl phosphate compounds such as tri-n-butyl phosphate. Furthermore, the protein solution obtained may be lyophilized.

The present invention furthermore relates to a product, more in particular Prothrombin Complex Concentrate, which is substantially free of (non-enveloped) viruses and is obtainable with the method of this invention.

5 The subject invention, which comprises a combination of a prefiltration followed by a nanofiltration, is applicable for every therapeutic protein present in a solution with a complex composition. Such protein solution could be derived from blood plasma, body tissue, fermentation broths or other biological
10 source materials. As stated before, the preferred starting material of this invention is PCC.

The high molecular weight contaminants that are typically removed by the prefiltration step have a molecular weight of at least 150 kD. Prefiltration removes, in the case of a blood
15 derived protein solution, in particular proteins such as: fibrinogen, fibronectin, Immunoglobulin M, coagulation factor VIII, coagulation factor XIII, von Willebrand factor and its multimeric forms, inter-alpha-inhibitor (=inter-alpha-trypsin-inhibitor), Alpha-2-macroglobulin, C1q complement protein, C4
20 complement protein, apolipoprotein(a), apolipoprotein B-100 and ferritin.

Use of nanofiltration is limited to therapeutic proteins having a molecular weight up to 150 kD. In the case of blood derived protein solutions, nanofiltration is limited to such
25 proteins as the coagulation factors II, VII, IX and X, protein S, protein C, albumin, antithrombin III, plasminogen, heparin cofactor II, Alpha-1-proteinase inhibitor, C1 inhibitor, transferrin, vitamin D-binding protein and immunoglobulin G.

The pretreatment and subsequent nanofiltration of PCC are
30 preferably operated as follows:

A. The first step is filtration of PCC over a 150 kD membrane in a tangential flow method at a transmembrane pressure of less than 0.5 bar. The filtrate passing through the prefilter is collected. During filtration, buffer is added
35 continuously to the retentate. The amount of buffer added is equal to the amount of filtrate obtained. Then, in a later stage of this filtration process, the addition of buffer is stopped. After completion of the prefiltration process the

amount of filtrate preferably is 4 to 6 times the amount of starting material.

During this prefiltration high molecular weight proteins in a molecular weight range of 400 kD or larger are removed from the PCC-solution. It was found that a similar prefilter with 300 kD membranes was not suitable for the essential removal of these high molecular weight components.

B. The second step is filtration of the prefiltered PCC over a 15 nm nanofilter in a dead-end filtration mode. During this process the 15 nm filtrate, i.e the flowthrough, is directly concentrated using hemodialysis cartridges in order to bring the coagulation factors to their desired concentration. The dead-end filtration mode is preferred to prevent a further dilution of the product and to prevent that characteristics of the product change, e.g. that the product becomes cloudy.

The filters used for prefiltration are available from Pall-Filtron (150 kD Omega low protein binding filters). The 15 nm nanofilter is available from Asahi Chemical Corp. Ltd (Tokyo, Japan). Suitable hemodialysis cartridges are available from several manufacturers, e.g. from Fresenius (HF 80).

The efficacy of the method for removal of non-enveloped viruses was studied by spiking the solution with a known amount of a model virus. For this study Canine Parvovirus (as a model for Human parvovirus B19) and Hepatitis A virus were used. These studies were performed on a scale that is 0.2 % of the production scale. The nanofiltration of PCC is capable of removing small non enveloped viruses to an extent of 5.0 to 6.0 on a 10-log scale.

The biochemical composition of nanofiltered PCC is only slightly altered when compared to unfiltered PCC. The level of coagulation factors and the concentration of excipients of freeze-dried nanofiltered PCC is similar to that of unfiltered freeze-dried PCC. In vivo and in vitro tests demonstrated that nanofiltration had no adverse effect on the product quality and characteristics.

The invention will be illustrated in more detail in the following examples.

Example 1

This example illustrates an experiment performed with 1000 ml of Prothrombin Complex Concentrate derived from the conventional production. Prothrombin Complex Concentrate was obtained from human blood plasma and had been subjected, prior to the prefiltration, to a sequence of steps involving ion exchange chromatography, chemical virus inactivation with 0.3% (w/w) Tri-n-butylphosphate (TNBP) and 1% (w/w) Tween 80, ion exchange chromatography and concentration.

Characteristics of Prothrombin Complex Concentrate:
Protein content: 25 mg per ml; Chemical composition: 10 mmol/l Na_3 -citrate, 500 mmol/l NaCl; pH 7.0.

Characteristics prefilter:
Manufacturer: Filtron; Type A: 200 kD polyethylene (PEAS) screen channel membrane; Effective surface area: 0.07 m².

Composition Filtration buffer:
10 mmol/l Na_3 -citrate, 500 mmol/l NaCl, pH 7.0.

Prothrombin Complex Concentrate was concentrated from 1000 ml to about 250 ml using the prefilter type A. Hereafter the volume of the retentate was kept at a constant level of 250 ml by continuously adding filtration buffer. After adding about 1000 ml of filtration buffer the addition of filtration buffer was stopped and concentration was continued. At the end of the process about 2000 ml of prefiltered Prothrombin Complex Concentrate was obtained.

The recovery of factor IX in the filtrate using the type A prefilter was about 73%. The average filtrate flow for the type A prefilter during the process was 9 liter per hour per m². This step was carried out at virtually no transmembrane pressure.

Example 2

This example illustrates an experiment performed with 1000 ml of Prothrombin Complex Concentrate derived from the conventional production. Prothrombin Complex Concentrate was obtained from human blood plasma and was passed, prior to the prefiltration, through a sequence of treatments involving ion exchange chromatography, chemical virus inactivation with 0.3%

(w/w) Tri-n-butylphosphate (TNBP) and 1% (w/w) Tween 80, ion exchange chromatography and concentration.

Characteristics of Prothrombin Complex Concentrate:

Protein content: 25 mg per ml; Chemical composition: 10 mmol/l

5 Na_3 -citrate, 500 mmol/l NaCl; pH 7.0.

Characteristics prefilter:

Manufacturer: Filtron; Type B: 300 kD polyethersulfon (PES) screen channel membrane; Effective surface area: 0.07 m².

Composition Filtration buffer:

10 10 mmol/l Na_3 -citrate, 500 mmol/l NaCl, pH 7.0.

Prothrombin Complex Concentrate was concentrated from 1000 ml to about 250 ml using the type B-prefilter mentioned above. Hereafter the volume of the retentate was kept at a constant level of 250 ml by continuously adding filtration
15 buffer. After adding about 1000 ml of filtration buffer the addition was stopped and concentration was continued. At the end of the process about 2000 ml of prefiltered Prothrombin Complex Concentrate was obtained. This step was performed at virtually no transmembrane pressure.

20 The recovery of factor IX in the filtrate using the type B prefilter was 66%. The average filtrate flow for the type B prefilter during the process was 26 liter per hour per m² area.

25 Example 3

This example illustrates an experiment performed with prefiltered Prothrombin Complex Concentrate derived from example 1.

Characteristics Nanofilter:

30 Manufacturer: Asahi Chemical, Tokyo, Japan; Type: 15 nm; Material: hollow fibers of cuprammonium regenerated cellulose; Effective surface area: 0.03 m²; Type of filtration: dead end; Configuration: one single filter.

A total volume of 2000 ml of prefiltered Prothrombin
35 Complex Concentrate was passed over the nanofilter in a dead-end filtration mode at a constant transmembrane pressure of 0.5 bar (recommendations of manufacturer). The filtrate flow decreased during the experiment from 14 to 10 liter per hour

per m². The factor IX recovery over the nanofilter was 79% as compared to the prefiltered Prothrombin Complex Concentrate.

Example 4

5 This example illustrates an experiment performed with prefiltered Prothrombin Complex Concentrate derived from example 2.

Characteristics Nanofilter:

Manufacturer: Asahi Chemical, Tokyo, Japan; Type: 15 nm;
10 Material: hollow fibers of cuprammonium regenerated cellulose;
Effective surface area: 0.03 m²; Type of filtration: dead end;
Configuration: one single filter.

Of the available 2000 ml prefiltered Prothrombin Complex Concentrate only about 1000 ml could be passed over the nano-
15 filter in a dead-end filtration mode at a constant transmembrane pressure of 0.5 bar (recommendations of manufacturer). The filtrate flow decreased during the experiment from 14 to 4 liter per hour per m². This indicates clogging of the nanofilter. The factor IX recovery over the nanofilter was
20 only 35% due to the premature termination of the filtration procedure.

Example 5

Four identical experiments were performed with 1000 ml of
25 Prothrombin Complex Concentrate derived from the conventional production. Prothrombin Complex Concentrate was obtained from human blood plasma and had been subjected, prior to the prefiltration, to subsequent treatments involving ion exchange chromatography, chemical virus inactivation with 0.3% (w/w)
30 Tri-n-butylphosphate (TNBP) and 1% (w/w) Tween 80, ion exchange chromatography and finally concentration.

Characteristics of Prothrombin Complex Concentrate:

Protein content: 25 mg per ml; Chemical composition: 10 mmol/l Na₃-citrate, 150 mmol/l NaCl; pH 7.0.

35 Characteristics prefilter:

Manufacturer: Filtron; Type A: 200 kD polyethersulfon (PES) screen channel membrane; Effective surface area: 0.07 m².

Composition Filtration buffer:

10 mmol/l Na_3 -citrate, 500 mmol/l NaCl, pH 7.0.

Prothrombin Complex Concentrate was concentrated in a stepwise fashion over the prefilter type A. The steps used, expressed as percentage of starting volume, were: 100 to 50%,
5 50 to 40%, 40 to 30% and 30 to 20%. After each concentration step the volume was kept constant by adding filtration buffer (about 250 ml per step). Only concentration was applied when the retentate was concentrated to about 20% of the starting
10 volume. At the end of the process about 3000 ml of filtrate was obtained. This filtration step was performed at virtually no transmembrane pressure.

The average recovery of factor IX in the filtrate using the type A prefilter was 94%. The filtrate flow during the process decreased from 20 to 7 liter per hour per m^2 .

15

Example 6

This example illustrates an experiment performed with a pool of four prefiltered Prothrombin Complex Concentrates (about 12 liters) derived from example 5.

20

Characteristics Nanofilter:

Manufacturer: Asahi Chemical, Tokyo, Japan; Type: 15 nm;
Effective surface area: 0.03 m^2 ; Type of filtration: dead end;
Configuration: two nanofilters serially connected.

During nanofiltration the filtrate flow decreased linear
25 from 16 to 11 liter per m^2 per hour. The recovery of factor IX was 96%.

Example 7

This example illustrates an experiment performed with the
30 nanofiltered Prothrombin Complex Concentrate derived from example 6.

Characteristic of Hemodialysis cartridge:

Manufacturer: Fresenius, Bad Homburg, Germany; Type: Hemoflow HF 80; Effective surface area: 1.8 m^2 ; Configuration: one
35 single hemodialysis cartridge.

Dialysis buffer:

Composition: 10 mmol/l Na_3 -citrate, pH 7.0.

During the steps described in examples 5 and 6 the PCC was diluted approximately four to five fold. This diluted nanofiltered Prothrombin Complex Concentrate was concentrated using a hemodialysis hollow fiber cartridge. After concentration the same hemodialysis cartridge was used for decreasing the ionic strength of the solution by dialysis against dialysis buffer until an ionic strength of 16 mS per cm was reached. The recovery of factor IX in this step was 92%.

10 Example 8

Four identical experiments were performed with 18 liter of Prothrombin Complex Concentrate derived from a conventional production. Prothrombin Complex Concentrate was obtained from human blood plasma and prior to prefiltration had been treated in subsequent steps involving ion exchange chromatography, chemical virus inactivation with 0.3% (w/w) Tri-n-butylphosphate (TNBP) and 1% (w/w) Tween 80, ion exchange chromatography and finally concentration.

Characteristics of Prothrombin Complex Concentrate:

20 Protein content: 25 mg per ml; Chemical composition: 10 mmol/l Na_3 -citrate, 500 mmol/l NaCl; pH 7.0.

Characteristics prefilter:

Manufacturer: Filtron; Type A: 200 kD polyethersulfon (PES) screen channel membrane; Effective surface area: 3.6 m²; Flow mode: tangential.

Characteristics Nanofilter:

Manufacturer: Asahi Chemical, Tokyo, Japan; Type: 15 nm; Effective surface area: 1 m²; Flow mode: dead end; Configuration: Two parallel sets of two serially connected 1 m² Planova filters.

Characteristic of Hemodialysis cartridge:

Manufacturer: Fresenius, Bad Homburg, Germany, Hemoflow HF 80; Effective surface area: 1.8 m²; Configuration: two parallel mounted hemodialysis cartridges.

35 Composition Filtration buffer:

10 mmol/l Na_3 -citrate, 500 mmol/l NaCl, pH 7.0.

Composition Dialysis buffer:

10 mmol/l Na₃-citrate, pH 7.0.

About 18 liters of Prothrombin Complex Concentrate was filtered over the prefilter with a transmembrane pressure of 0.3 bar. Prior to prefiltration the product was recirculated starting at a transmembrane pressure of 0.7 bar. Every five minutes the transmembrane pressure was decreased with 0.1 bar to a final operation transmembrane pressure of 0.3 bar. In this recirculation phase a gel layer was formed on the membrane which prevented 'throughput' of high molecular weight proteins. This resulted in about 60 liter prefiltered nanofiltrate which was subsequently passed over two parallel sets of two serially connected nanofilters. The filtrate derived from nanofiltration was concentrated in line four to six fold with two parallel mounted hemodialysis cartridges. Hereafter the ionic strength was reduced to 16 mS/cm by dialysis against dialysis buffer using the same hemodialysis cartridges. The recovery of factor IX for these four large scale experiments was about 72% as compared to the starting material.

Example 9

Three identical experiments were performed with 20 liter of Prothrombin Complex Concentrate derived from a conventional production. Prothrombin Complex Concentrate was obtained from human blood plasma and prior to prefiltration had been treated in subsequent steps involving ion exchange chromatography, chemical virus inactivation with 0.3% (w/w) Tri-n-butyl-phosphate (TNBP) and 1% (w/w) Tween 80, ion exchange chromatography and finally concentration.

Characteristics of Prothrombin Complex Concentrate:

Protein content: 15-25 mg per ml; Chemical composition: 10 mmol/l Na₃-citrate, 500 mmol/l NaCl; pH 7.0.

Characteristics prefilter:

Manufacturer: Filtron; Type C: 150 kD polyethersulfon (PES) screen channel membrane; Effective surface area: 3.6 m²; Flow mode: tangential.

Characteristics Nanofilter:

Manufacturer: Asahi Chemical, Tokyo, Japan; Type: 15 nm;
Effective surface area: 1 m²; Flow mode: dead end;
Configuration: one set of two serially connected 1 m² Planova
filters.

5 Characteristics of Hemodialysis cartridge:

Manufacturer: Fresenius, Bad Homburg, Germany, Hemoflow HF 80;
Effective surface area: 1.8 m²; Configuration: two parallel
mounted hemodialysis cartridges.

Composition Filtration buffer:

10 10 mmol/l Na₃-citrate, 500 mmol/l NaCl, pH 7.0.

Composition Dialysis buffer:

10 mmol/l Na₃-citrate, pH 7.0.

About 20 liters of Prothrombin Complex Concentrate was
filtered over the prefilter as described in Example 8. This
15 resulted in about 60 liter prefiltered nanofiltrate which was
subsequently passed over two serially connected nanofilters.
The filtrate derived from nanofiltration was concentrated in
line four to six fold with two parallel mounted hemodialysis
cartridges. Hereafter the ionic strength was reduced to
20 16 mS/cm by dialysis against dialysis buffer using the same
hemodialysis cartridges. The recovery of factor IX for these
three large scale experiments was about 50-70% as compared to
the starting material.

25 Example 10: Virus removal studies with Planova 15N

The virus removal capacity of nanofiltration was studied
by spiking prefiltered Prothrombin Complex Concentrate with
relevant viruses such as Human Immunodeficiency Virus (HIV)
and Hepatitis A Virus (HAV), and model viruses such as Bovine
30 Viral Diarrhoea Virus (BVDV), Pseudo Rabies Virus (PSR),
Encephalomyocarditis Virus (EMC), and Canine Parvovirus (CPV).
EMC, HAV and CPV are viruses belonging to the class of non-
enveloped viruses. EMC, HAV and CPV have a diameter of 20 to
25 nm. CPV is considered to be a model virus for Human
35 Parvovirus B19.

These spiking studies were performed on a scale of 100 ml
(this is about 0.2% of the industrial scale) of prefiltered
Prothrombin Complex Concentrate derived from example 1. The

material spiked with the above mentioned viruses was passed over two serially connected Planova 15N filters with a surface area of 0.003 m² each. The virus titer was determined in the prefiltered material and in the nanofiltered Prothrombin Complex Concentrate. The virus removal is expressed as a logarithmic reduction factor (in 10 log-metric).

The results of the studies are given in table 1.

Table 1

10	virus studied	Size (nm)	Lipid envelope	Physico-chemical Resistance	Removal by nanofiltration over serially connected Planova filters (10 log-metric)
15	-----				
	HIV	80-120	Yes	Low	> 7.0
	BVDV	40	Yes	Intermediate	> 5.9
	PSR	120-200	Yes	Intermediate	> 6.2
20	EMC	20	No	Intermediate	> 7.3
	CPV	20	No	High	> 5.1
	HAV	25	No	High	> 5.9

These data show that nanofiltration is capable of reducing the virus load of the prefiltered Prothrombin Complex Concentrate with a factor of 10⁵ - 10⁷ for viruses with a size of 20 to 25 nm and above.

CLAIMS

1. A method for removing viruses from a protein solution, comprising subjecting said mixture to a pretreatment which removes large proteins and subjecting the resulting product to nanofiltration which removes viruses.
- 5 2. A method according to claim 1, wherein said protein solution is a blood derived protein solution.
3. A method according to claim 1, wherein said protein solution contains proteins selected from the group consisting of coagulation factors II, VII, IX, X, Protein C, Protein S,
10 albumin, antithrombin III, plasminogen, heparin cofactor II, Alpha-1-proteinase inhibitor, C1 inhibitor, transferrin, vitamin D-binding protein and immunoglobulin G.
4. A method according to claim 1, wherein said protein solution contains vitamin K dependent blood plasma proteins.
- 15 5. A method according to claim 1, wherein said protein solution is Prothrombin Complex Concentrate.
6. A method according to claim 1, wherein said large proteins have a molecular weight larger than about 200 kD.
7. A method according to claim 1, wherein said large
20 proteins have a molecular weight of from about 400 kD to about 20,000 kD.
8. A method according to claim 1, wherein said large proteins are selected from the group consisting of fibrinogen, fibronectin, immunoglobulin M, coagulation factors VIII, XIII,
25 von Willebrand factor and its multimeric forms, inter-alpha-(trypsin)-inhibitor, alpha-2-macroglobulin, C1q complement protein, C4 complement protein, apolipoprotein(a), apolipoprotein B-100 and ferritin.
9. A method according to claim 1, wherein said pretreatment
30 comprises membrane filtration over a membrane having a cut-off value of between about 100 to about 250 kD, preferably about 150 kD.
10. A method according to claim 1, wherein said pretreatment comprises membrane filtration carried out in a tangential flow

filtration mode at a transmembrane pressure of less than 0.5 bar.

11. A method according to claim 10, wherein during filtration a buffer is added to the retentate and the filtration process
5 is stopped when the amount of filtrate is about 4 to 6 times the amount of starting material.

12. A method according to claim 1, wherein said nanofiltration is carried out over a nanofilter having a cut-off value of between about 10 to about 30 nm, preferably about 15 nm.

10 13. A method according to claim 1, wherein said nanofiltration is carried out in a dead-end filtration mode.

14. A method according to claim 1, wherein the nanofiltrate is concentrated by dia- or ultrafiltration, preferably in a hemodialysis cartridge.

15 15. A method according to claim 1, wherein said viruses are non-enveloped viruses.

16. A method according to claim 1, wherein said viruses are non-enveloped viruses having a diameter of 20 nm or more.

17. A method according to claim 1, wherein said viruses are
20 non-enveloped viruses selected from the group consisting of Hepatitis A Virus, parvoviruses such as Human Parvovirus B19 and Canine Parvovirus, and Encephalomyocarditis Virus.

18. A method according to claim 1, further including a virus inactivation, preferably before said pretreatment, by treating
25 the protein solution with detergents such as ionic and/or non-ionic detergents in the presence of di- or trialkyl phosphate compounds such as tri-n-butyl phosphate.

19. A method according to claim 1, wherein the protein solution obtained is lyophilized.

30 20. A product substantially free of viruses, obtainable with the method of any one of claims 1 to 19.

21. A Prothrombin Complex Concentrate substantially free of viruses, obtainable with the method of any one of claims 1 to 19.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 98/00108

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K1/34 C07K14/745 C12N9/74 C07K14/755

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 34947 A (NEW YORK BLOOD CENTER) 7 November 1996 see throughout, especially example 11 ---	1-21
X	CHEMICAL ABSTRACTS, vol. 121, no. 24, 12 December 1994 Columbus, Ohio, US; abstract no. 286409, XP002067615 & M BURNOUF-RADOSEVICH ET AL.: "Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates" VOX SANGUINIS, vol. 67, no. 2, 1994, pages 132-138, see abstract --- -/--	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

10 June 1998

Date of mailing of the international search report

22/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Masturzo, P

INTERNATIONAL SEARCH REPORT

Inter. J. Appl. Application No

PCT/NL 98/00108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 121, no. 26, 26 December 1994 Columbus, Ohio, US; abstract no. 308095, XP002067616 & M POULLE ET AL.: "Large-scale preparation of highly purified C1-inhibitor for therapeutic use" BLOOD COAGULATION FIBRYNOLYSIS, vol. 5, no. 4, 1994, pages 543-549, see abstract -----	1-20
X	WO 96 00237 A (PHARMACIA AB) 4 January 1996 cited in the application See throughout, especially page 9, lines 4-10 and the examples -----	1-21
A	File Medline, abstract 97019642, 1997 XP002067614 & J RÖMISCH ET AL.: "Nanofiltration bei der Herstellung von Beriplex P/n: Erhöhung der Kapazität zur Viruseliminierung unter Beibehaltung der Produktqualität " BEITRÄGE ZUR INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN, vol. 33, 1996, pages 220-224, cited in the application see abstract -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 98/00108

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9634947 A	07-11-1996	US 5677162 A AU 5632096 A	14-10-1997 21-11-1996
WO 9600237 A	04-01-1996	SE 502820 C AU 682274 B AU 2813295 A DE 796269 T EP 0796269 A ES 2105992 T FI 965145 A JP 10502074 T NO 965523 A SE 9402254 A	22-01-1996 25-09-1997 19-01-1996 02-01-1998 24-09-1997 01-11-1997 20-12-1996 24-02-1998 20-12-1996 24-12-1995